Eisai Signs a License Agreement with FUJI YAKUHIN for Dotinurad to Treat Hyperuricemia and Gout in China
Shots:
- FUJI YAKUHIN to receive up front- development & commercial milestones and will manufacture the formulation of dotinurad and supply it to Eisai while Eisai will get exclusive development and marketing rights for therapy and will be responsible for regulatory submission in China
- FUJI YAKUHIN is expecting the maximum value of dotinurad in China by leveraging Eisai's expertise for global expansion of dotinurad. The collaboration will provide new treatment options for hyperuricemia and gout and improves QoL of patients in China
- Dotinurad is selective URAT1 inhibitor- act by suppressing uric acid reabsorption and lowering blood uric acid levels
Click here to read full press release/ article | Ref: Eisai | Image: Eisai
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
